INTRODUCTION
Psoriasis (Ps) is a chronic inflammatory disease with a multifactorial origin that has a considerable impact on health-care. Cytokines have an important role in the pathogenesis of the disease by mediating intercellular communication between immune cells that infiltrate the skin and keratinocytes. 1 The prevalence of Ps varies with geographic location and has been reported to range from 1%-3%. 2, 3 Family and twin studies show that genetic predisposition has a major role in the development of Ps. 4 In addition, several studies have reported that environmental factors can trigger the disease. 5 Genome-wide association studies (GWAS) have uncovered several Ps-related chromosomal regions, such as the receptors for interleukin (IL)-23 and IL-12B. 6, 7 The major histocompatibility complex human leukocyte antigen-Cw6 region, however, has been consistently associated with Ps (present in 67% of patients versus 15% of the general population). 8 Ps is a complex disease that can occur simultaneously with other inflammatory disorders such as psoriatic arthritis (PsA) in 10-30% of cases. 2 In addition, Ps shares pathophysiological mechanisms with PsA, rheumatoid arthritis (RA) and Crohn's disease (CD). These disorders involve a strong genetic component and can be treated with the drugs used to treat Ps. 9, 10 Several agents are available for the treatment of Ps, including biologics that selectively block tumor necrosis factor (TNF)-a (infliximab, adalimumab and etanercept).
The regular tool for assessing efficacy of treatment of Ps in clinical trials is Ps area and severity index (PASI) score. The European Medicines Agency has recognized PASI-75 response (75% improvement from baseline PASI) as an indicator for severe Ps response to treatment in clinical trials. According to European Medicines Agency, an 8-to-12-weeks study is generally sufficient to show short-term efficacy. 11, 12 The anti-TNF agents are effective in the treatment of Ps (XPASI-75 in 50-80% of patients at 12 weeks). However, these drugs are not effective in all patients and do not cure the disease. Moreover, they are expensive and can also produce long-term toxicity. 13, 14 Consequently, it is necessary to further investigate the pathogenesis of Ps to find new therapeutic targets that enable the development of more effective drugs. It is also important to search for new biomarkers, in particular, genetic polymorphisms that can predict which patients will respond to a specific drug. Identification of pharmacogenetic markers that allow us to treat only those patients who will respond without the risk of adverse events would significantly optimize the efficiency of therapy and reduce costs.
This review is based on current knowledge of the genetic basis of the pathogenesis of Ps and of the relationship between Ps and other autoimmune diseases (PsA, RA and CD). We examined the association between these diseases and response to biological treatments. We propose to identify genetic biomarkers that could possibly be associated with response to the treatment of Ps with anti-TNF.
IMMUNOPATHOGENESIS AND GENETICS OF PS AND RELATED AUTOIMMUNE DISEASES
Failure of the immune system to recognize autologous tissues or components of the immune system as self leads to inflammation, injury and death of healthy cells, as well as onset of autoimmune diseases such as Ps, PsA, RA and CD. The exact cause of loss of recognition of self is not well known.
Several studies have associated Ps, PsA, RA and CD with an immune response involving the helper T cells Th1 and Th17 that is triggered by bacterial infection or an environmental stimulus. 15 Antigens cross the epithelium through cells and are phagocytized by antigen-presenting cells (APCs) such as macrophages and dendritic cells. Naive CD4 þ T cells become activated by cytokines such as TNF-a, IL-1, IL-6 and chemokines and inflammatory molecules released by APCs after an environmental stimulus or infection (Figure 1) .
The influx of activated leukocytes and monocytes leads to the production of inflammatory mediators that amplify inflammation and cause tissue injury. 16 IL-1, IL-6 and TNF-a are the major APCs derived from the cytokines present in the rheumatoid joint. All of these agents cause aberrant activation of osteoclasts and joint erosion in patients with RA. 15, 17, 18 Increased levels of proinflammatory cytokines (TNF-a, IL-6 and IL-1b), favoring the recruitment of leukocytes intensify the inflammatory response. 19 These cytokines have a major role in the perpetuation of intestinal inflammation in CD, resulting in an imbalance between proinflammatory and anti-inflammatory cytokines. 20 They also have an important role in the mechanism of arthritic bone destruction, because they induce the receptor activator of NF-kB (RANK) in synovial fibroblasts, which require RANK ligand (RANKL) to trigger the differentiation of osteoclast precursor cells into activated osteoclasts. This process results in bone resorption and the eventual manifestation of PsA. 21 T cells also express RANKL. In contrast, levels of interferon-g (IFN-g), a potent RANKL inhibitor produced by T cells, are very low. This imbalance may be responsible for the aberrant activation of osteoclast formation in arthritis. 22 Activated APCs release other proinflammatory cytokines such as IL-12, IL-18, IL-15, IL-6 and IL-8, and, together with TNF-a and IL-1, they acquire the ability to drive T-cell differentiation and activation into Th1 that produce IFN-g. Other cytokines produced by APCs include IL-19, IL-20 and IL-24, which cause alteration of keratinocytes in psoriatic skin. 1 IL-18 maintains the response of Th1, whose production is increased in CD. 23 Th1 cells develop mainly as a result of cytokine IL-12 production by macrophages and increased production of IFN-g by T cells. 16 Recent studies have associated polymorphisms in IL-12B (rs6887695 and rs3212227) with Ps in Caucasian patients. 7 These findings have been confirmed elsewhere, 6, [24] [25] [26] and single-nucleotide polymorphisms (SNPs) have been detected in Caucasian patients with CD, 27, 28 PsA 29, 30 and RA. 31 However, Varade et al. 32 found no association between these SNPs and RA, although their data suggest that IL-23R contributes to the etiology of RA (Table 1) .
Activated Th1 also increase production of TNF-a, which acts on intestinal fibroblasts and leads to the release of IL-13 and transforming growth factor-b (TGF-b), which causes fibrosis and stricture formation in CD. 33 The role of IL-13 and IL-4 is unclear, although genetic variations may result in deregulation of the Th1 and Th17 pathways. 34 SNPs in the IL-13 gene (rs2054, rs848 and rs1800925) have been associated with Ps 31, 35, 36 and PsA. 37 Eder et al. 38 associated these polymorphisms with increased susceptibility to PsA in patients with Ps.
The SNPs rs20541 and rs1800925 were found to be closely associated with susceptibility to PsA. However, Bowes et al. 39 found that neither was significantly associated with susceptibility to Ps vulgaris. Li et al. 40 suggested that the most significant 5q31 variants (including rs1800925 in the IL-13 gene) associated with Ps were not significant in CD. Therefore, association with CD and Ps in this region seems to result from the presence of different variants. As for RA, the results of Marinou et al. 41 indicated that common variants of the IL-4/IL-13 pathway did not significantly contribute to susceptibility to this disease. APCs also secrete IL-23. Overexpression of IL-23, which induces epidermal proliferation, has been detected in lesional psoriatic skin. Some GWAS have identified IL-23R and other genes involved in the differentiation of Th17 cells (for example, Ps, PsA, RA and CD susceptibility genes). The SNP rs11209026 has been associated with Ps 7, 24, 27, 42 and PsA. 29, 30, 43, 44 However, Huffmeier et al. 45 indicated that this polymorphism is relevant for susceptibility to Ps in general, even though it is not a specific risk factor for arthritis. In contrast, other authors found associations between rs11209026 and RA. 31 Moreover, this uncommon coding variant (Arg4Gln) confers strong protection in CD. [46] [47] [48] The polymorphisms rs7530511 and rs2201841 in IL-23R have also been associated with autoimmune diseases. rs7530511 was associated with Ps, PsA and RA, although no references were found for CD. rs2201841 has been associated with susceptibility to Ps 36 and CD. 47 Several studies suggest that IL-23 is an essential promoter of chronic joint inflammation in RA; however, Park et al. 49 found no statistically significant differences in this SNP of the IL-23R gene. Other authors, however, reported that rs2201841 was a risk factor for RA as well as CD 50 (Table 1 ). In Ps, high concentrations of TGF-b inhibit expression of IL-23R and favor the development of T regulatory (Treg) cells. 34 IL-23, IL-6 and IL-1b inhibit the development of Treg cells but are necessary for differentiation of Th17. 19 The IL-1b promoter region polymorphisms rs16944 and rs1143634 have been associated with increased susceptibility to Ps 51 and RA. 52 In addition, Ravindran et al. 53 noted an increased frequency of IL-1b rs1143634 among Caucasian PsA patients. The results of univariate tests to establish associations between genotypes and diseases performed by Rhaman et al. 54 revealed a significant association between rs16944 and increased risk of PsA. However, other authors found no evidence for an association between these polymorphisms and PsA. 9, 55 One meta-analysis showed a significant association between the rs16944 allele G variant and RA in a Caucasian population. 56 The results of Celik et al. 57 suggested that this polymorphism was not an important risk factor in susceptibility to inflammatory bowel diseases, such as CD. However, Ferreira et al. 58 found no association between this SNP and an increased risk of CD. The polymorphism rs1143634 in the IL-1b gene has been associated with RA and with severity of and susceptibility to inflammatory bowel disease, 59 ,60 and rs1143634 has been described as a potentially important marker of the severity of joint destruction in patients with RA. 61 Treg can produce IL-10 and TGF-b, which inhibit Th1 differentiation while promoting Treg differentiation. 19 Several studies have suggested that polymorphisms in the IL-10 promoter (position-1082 (rs1800896), position-819 (rs1800871) and position-592 (rs1800872)), but not in IL-1b, have a role in the etiology of CD. Other authors have not found any association between these polymorphisms and CD, Ps or PsA. [62] [63] [64] [65] Nevertheless, the results of Kingo et al. 66 show that the IL-10 ACC haplotype (-1082, -819 and -592) has a role in determining the severity and course of plaque Ps. Settin et al. 67 showed a significantly higher frequency of the IL-10 -1082 GG genotype in patients with Ps than in healthy controls. Other studies have suggested that patients with late-onset Ps (over 40 years) were more likely to be heterozygous at position -1082 (P ¼ 0.02). 68 In addition, this SNP has been described as a relevant risk factor for developing CD in a Spanish population 69 and has been implicated in susceptibility to RA (GG þ GA genotypes had a 25% decreased 70 The meta-analysis by Lee et al. 71 suggested that the -592 CA polymorphism confers susceptibility to RA in Asians and that the IL-10 -1082 GA polymorphism is associated with susceptibility to RA. Activated Th17 cells, mainly those activated by IL-23, secrete proinflammatory cytokines (IL-17, IL-22, IL-21, IL-6, IL-26 and TNF-a) that cause hyperproliferation and poor differentiation of keratinocytes and robust mononuclear inflammation in Ps. In patients with PsA, secretion of these cytokines by Th17 cells led to joint inflammation, enthesitis, cytokine-induced osteoclastogenesis and bone resorption by CD68 þ osteoclasts. 34, 72 Several studies have found an association between specific SNPs in the IL-21 gene (rs6822844) and susceptibility to Ps, PsA, 73 RA 74 and CD. 75, 76 TNF-a is generated and expressed by several types of immune cells, namely, dendritic cells, macrophages, Th1 cells and Th17 cells. It mediates numerous inflammatory and immunoregulatory activities. The important role of this proinflammatory cytokine in the pathogenesis of Ps, PsA, RA and CD is also supported by GWAS, which have demonstrated that the SNPs in the TNF-a gene (rs1800629, rs361525 and rs1799724), also known as TNF-a -308, TNF-a -238 and TNF-a -857, respectively, have been linked to a wide variety of conditions.
The SNPs rs1800629 and rs361525 are strongly associated with Ps and PsA, 67, [77] [78] [79] [80] and the results of several studies suggest that rs1800629 is associated with an increased risk of early-onset Ps, presence of joint erosions in PsA (Po0.0001) and progression of joint erosions in early PsA. 51, 81, 82 Other authors confirmed the association between TNF-a -238 and early-onset Ps. 83, 84 In addition, Arias et al. 85 suggested that heterozygosity at the TNF-a -238 locus is associated with increased susceptibility to type I Ps. According to these results, polymorphisms in TNF-a may be useful prognostic markers in Ps and PsA, although this hypothesis requires further evaluation. 86 In contrast, Kim et al.
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found no significant differences in the polymorphisms TNF-a -238 and TNF-a -308 between Ps patients and controls in the Korean population.
Other authors have reported an association between rs1800629 and an increased risk of RA or CD. 58, 88 Moreover, Nemec et al.
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suggested an association between-308 GA and the severity of RA. In summary, Ps shares pathological mechanisms with PsA, RA and CD. Attention has focused on inhibition of TNF-a, which can be a successful mean of treating these diseases when an abnormality of the LTh1 pathway has an important role in its pathogenesis. 18 Table 1 shows several polymorphisms in TNF-a and IL-23, IL-12B, IL-13, IL-21, IL-1A, IL-1B and IL-10 that have been associated with these diseases in GWAS or candidate gene studies.
GENETIC POLYMORPHISMS ASSOCIATED WITH RESPONSE TO ANTI-TNF TREATMENT
To date, no highly specific and/or sensitive genetic predictors of the outcome of anti-TNF therapy have been identified. 90 Pharmacogenetic studies focusing on the genes involved in the etiology of Ps, PsA, RA and CD and on the pharmacokinetics of anti-TNF agents have identified markers that could be associated with the outcome of anti-TNF treatment (Table 2) .
Polymorphisms in the TNF-a gene promoter are significantly associated with severity and response to treatment of RA. 89, 91, 92 Lee et al. 93 found an association between response to infliximab and the TNF-a -238 A4G polymorphism (P ¼ 0.039) in RA, but not with the TNF-a -308 A4G polymorphism. In contrast, Mugnier et al. 94 suggested that patients with the -308 GG genotype respond better to infliximab than patients with the AA or AG genotypes. Other authors have associated -238G, -308G and -857C alleles in the TNF-a gene with a lower response to adalimumab in RA. 95 Moreover, Guis et al. 96 concluded that RA patients who are homozygous for the TNF-a -308G allele respond to etanercept better than patients who are heterozygous for this allele. Seitz et al. 97 confirmed that patients with the -308 GG genotype respond better to anti-TNF treatment than those with the AA or AG genotypes in RA and even in PsA.
The differences in the therapeutic effects of infliximab among patients with CD may be explained in part by the presence of the TNF-a -857 C4T polymorphism. 98 As stated above, evidence of a strong association between the TNF-a promoter polymorphisms at positions -238 and -308 and Ps and PsA has been found. 77, 79 Moreover, other meta-analyses suggested that both polymorphisms could be used as biomarkers to predict the risk of Ps and PsA. 78, 80 Other authors have found an association between the polymorphism TNF-a -857 (C allele) and rs1061622 in TNFRSF1B (T allele) and good response to etanercept in patients with Ps (P ¼ 0.002 and P ¼ 0.001, respectively); however, they did not find the same association for infliximab or adalimumab. 99 Therefore, TNF-a polymorphisms may be a useful tool for predicting response to anti-TNF treatment in patients with Ps.
SNPs of TNF receptor superfamily 1A (TNFR1A) (rs767455) and TNFR1B (rs1061624 and rs3397) were evaluated in Japanese patients with CD. 100 The minor allele of rs767455 was associated with a lack of efficacy of infliximab than the major genotype. This finding was confirmed by Pierik et al. 101 In addition, the AT haplotype (rs1061622 A allele and rs3397 T allele) also showed significant differences in their distribution between responders and nonresponders (P ¼ 0.01). 100 In contrast, a previous study conducted in Caucasian population concluded that TNFR1A and TNFR1B polymorphisms could be thoroughly excluded as pharmacogenomic markers for a treatment response to infliximab in CD. 102 These controversial results may be explained by the possible genetic differences between races.
The SNP rs1061622 (mutant 196Arg allele) on the TNFR1B gene has been associated with a poorer response to anti-TNF therapy, independently of the specific agent used. This polymorphism could prove to be a useful genetic marker for predicting the degree of response to anti-TNF therapy. 103 In this sense, the response to infliximab in CD and RA was associated with rs1061622, but not with other polymorphisms (TNF-a promoter -238, -308, -857 and rs767455). 104 However, larger studies are needed to confirm the relevance of these associations.
The TNFAIP3 gene has been associated with Ps, 36 PsA and RA, as well as with other autoimmune disorders. 105, 106 The G allele of rs610604 located in the TNFAIP3 gene was associated with a good response to therapy all anti-TNF agents (P ¼ 0.05) and etanercept (P ¼ 0.016). 107 Its haplotype with the T allele of rs2230926 are markers of a positive response to anti-TNF agents 107 in Ps. Nevertheless, in a study performed in RA patients no association was found between other polymorphisms in this gene and good response to anti-TNF treatment. 108 Polymorphism in the LTA gene (rs909253) has been associated with poorer response to anti-TNF treatment in CD (homozygotes for LTA NcoI-TNFc-aa13L-aa26 haplotype 1-1-1-1) . 109 This SNP has also been significantly associated with the presence of joint erosions in PsA. 81 The LTA gene has been associated with response to etanercept in RA, 92 but no association was found with response to infliximab in CD. 110 Polymorphisms in the fraction constant gamma receptor gene (FCGR) affect the affinity of the receptor for immunoglobulin, which may in turn affect the efficacy of immunoglobulin-based therapies. The response to infliximab in patients with RA is affected by the FCGR2A (rs1801274, 131 H4R) and FCGR3A (rs396991, 158 V4F) genotypes in RA. 111 Lee et al. 112 found no relation between the polymorphism in FCGR2A and susceptibility to RA in Europeans or Asians. However, the polymorphism in FCGR3A was associated with RA in Europeans but not in Asians. This polymorphism in the FCGR3A gene (FF genotype) may be associated with positive response after 12 weeks treatment with anti-TNF agents in RA. However, patients with RR genotype in FCGR2A gene showed a good and moderate response at 30 week of treatment. 113 The authors concluded that the influence of these genes are complex and dynamic and requires an exhaustive evaluation of patients at different time points. Other authors have reported that the mechanism of the reduced clearance of infliximab in patients with RA could be explained in part by polymorphisms in FCGR.
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Other study has concluded that the SNP rs4962153 in the promoter region of the TTP (tristetraprolin) gene mildly affects promoter activity and, thus, disease duration in patients with RA. Specifically, patients with the GG genotype had a shorter disease duration than patients with the AA/AG genotypes and, therefore, a higher probability of response to infliximab. 115 Two SNPs in MAP3K gene were involved in the response to anti-TNF therapy in a sample of 428 patients with RA. 116 Carrying the minor allele of rs96844 was associated with good treatment response, whereas carrying the minor allele of rs4792847 was associated with a reduced treatment response. However, in a replication study of association with a complete cohort (n ¼ 1070) neither of these associations were found. 116 A study evaluates the association between response to etanercept and nine SNPs in patients with RA (Table 2) . 117 The results of this study indicated that patients carrying the minor allele in rs11986055 (IKBKB), rs11541076 (IRAK-3) and rs7744 
Abbreviations: A, adalimumab; CD, Crohn's disease; E, etanercept; I, infliximab; IL, interleukin; MAF, minor allele frequency (data from web page Hapmap 123 and Alfred 126 in Caucasian population); Ps, psoriasis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SNP, single-nucleotide polymorphism; TNF, tumor necrosis factor. kindicates allele associated with non-response andmindicates a greater chance of achieving a moderate/good response with anti-TNF therapy. K indicates an association between the disease and an SNP. *indicates that the data come from GWAS and # indicates that the data come from candidate genes studies. **rs1061624 (A allele) and rs3397 (T allele) did not independently associate with infliximab efficacy, but the AT haplotype had a significant difference in distribution in responders and nonresponders. 100 ***LTA NcoI-TNFc-aa13L-aa26 haplotype 1-1-1-1k.
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(MyD88) had a greater chance of achieving a moderate/good response with anti-TNF therapy compared with major homozygotes. In contrast, lower probability of good response was associated with the minor allele of rs11591741 in CHUK gene. 117 In a prospective GWAS performed on 89 RA patients who started treatment with anti-TNF agents, significant associations with treatment response were observed with multiple SNPs (Table 2) . 118 An association between a combination of alleles influencing production of IL-1 receptor antagonist (A2 allele) and TGF-b1 (rs1800471, C allele) and nonresponsiveness to etanercept in patients with RA have been found by Padyukov et al.
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Analyses of multivariate logistic regression were used to evaluate the association between 31 RA alleles risk selected in a bibliographic revision and the response to anti-TNF therapy in 1283 patients (infliximab n ¼ 625, etanercept n ¼ 502 and adalimumab n ¼ 156). 108 The authors have observed statistically significant associations between favorable response to anti-TNF therapy and the major allele of rs10919563 in the protein tyrosine phosphatase, receptor type 2 (PTPRC) gene. 108 This gene is essential in regulation of signaling of lymphocytes and monocytes (mediators of TNF-a secretion). The authors have not seen the effects of certain polymorphisms in genes TRAF6, IL-2RA, TNFRSF14, CD40, CD28, IL-2-IL-21, IL-2RB, CDK6 and STAT4 (not included in Table 2 ) on RA risk or response to anti-TNF therapy. 108 In summary, only two studies have described markers of good response to anti-TNF agents in patients with Ps. One showed that rs610604 (G allele) located in the TNFAIP3 gene and its haplotype with rs2230926 (T allele) are markers of a positive response to anti-TNF agents. 107 The other study suggested that polymorphisms in TNF-a -857 (rs1799724) and TNFRSF1B (rs1061622) can predict a good response to etanercept, but not to infliximab or adalimumab. 99 These SNPs were studied in RA and CD, both of which share pathogenic mechanisms with Ps, and a genetic association between RA or CD and Ps has been suggested (Table 2 ). Therefore, SNPs that have been associated with a response to anti-TNF treatment in patients with RA or CD should be investigated in patients with Ps.
This review has some limitations. First, although there has been an extensive review of literature, by space limits, it only collects those polymorphisms that are considered more relevant and interesting to study in future research. Second, this review does not include genes that may be related to Ps susceptibility or response to other drugs used in its treatment, such as ustekinumab, methotrexte or retinoids. Moreover, it is possible that polymorphisms with high clinical importance have not yet been investigated. Therefore, larger studies are needed to confirm the relevance of the association found between polymorphisms and response to anti-TNF treatment in Ps and other related autoimmune diseases, as well as for discovering new SNPs.
CONCLUSION
Advances in the treatment of specific diseases with a strong autoimmune component, such as Ps, are imminent, as a result of testing with genetic biomarkers. However, much work remains to be done. Few studies analyze Ps, and those that do evaluate a single disease and are mostly unconfirmed. It is therefore necessary to search for new genetic markers or analyze previously studied biomarkers in other Ps-related diseases. Improved knowledge can make it possible to tailor therapy and reduce unnecessary toxicity in patients with Ps receiving anti-TNF therapy. Large prospective studies are necessary to validate markers before implementation in daily clinical practice. 88 
